Emcure Pharmaceuticals · NSE: EMCURE · BSE: 544210
Q1 FY26 results · Apr–Jun 2025
Emcure Pharmaceuticals reported revenue from operations of ₹2,100.54 crore (up 15.7% from Q1 FY25) and net profit of ₹214.79 crore (up 40.8% from Q1 FY25) for Q1 FY26 (Apr–Jun 2025), on a consolidated basis.
| Item | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,100.54 | 1,815.14 | +15.7% | 2,116.24 | −0.7% |
| Other income | 3.70 | 23.44 | −84.2% | 4.45 | −17.0% |
| Total income | 2,104.23 | 1,838.58 | +14.4% | 2,120.70 | −0.8% |
| Profit before tax | 290.76 | 207.41 | +40.2% | 260.61 | +11.6% |
| Net profit for the period | 214.79 | 152.59 | +40.8% | 197.24 | +8.9% |
| Attributable to shareholders of the company | 206.95 | 144.08 | +43.6% | 188.96 | +9.5% |
| EPS, basic (₹) | 10.92 | 7.95 | +37.4% | 9.97 | +9.5% |
| Net margin (%) | 10.2 | 8.4 | 9.3 |
| Item | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,096.57 | 970.29 | +13.0% | 1,278.19 | −14.2% |
| Other income | 21.52 | 32.51 | −33.8% | 22.40 | −3.9% |
| Total income | 1,118.10 | 1,002.80 | +11.5% | 1,300.58 | −14.0% |
| Profit before tax | 165.67 | 55.05 | +201.0% | 186.05 | −11.0% |
| Net profit for the period | 122.79 | 40.45 | +203.6% | 139.56 | −12.0% |
| EPS, basic (₹) | 6.48 | 2.23 | +190.6% | 7.37 | −12.1% |
| Net margin (%) | 11.2 | 4.2 | 10.9 |
Consolidated
- Filed with BSE
- 07 Aug 2025, 13:53 IST
- Board meeting
- 07 Aug 2025
- Period
- 01 Apr 2025 to 30 Jun 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 07 Aug 2025, 13:53 IST
- Board meeting
- 07 Aug 2025
- Period
- 01 Apr 2025 to 30 Jun 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE